These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Susceptibility to cyclosporin A-induced autoimmunity: strain differences in relation to autoregulatory T cells. Barendrecht MM; Tervaert JW; van Breda Vriesman PJ; Damoiseaux JG J Autoimmun; 2002 Feb; 18(1):39-48. PubMed ID: 11869045 [TBL] [Abstract][Full Text] [Related]
24. Autologous graft-vs-host disease: mechanisms and potential therapeutic effect. Hess AD; Jones RC; Santos GW Bone Marrow Transplant; 1993; 12 Suppl 3():S65-9. PubMed ID: 8124261 [TBL] [Abstract][Full Text] [Related]
25. Prevention of cyclosporine-induced syngeneic graft-versus-host disease in bone marrow transplantation by UV-B irradiated bone marrow cells. Ohajekwe OA; James T; Hardy MA; Oluwole SF Bone Marrow Transplant; 1995 Apr; 15(4):627-32. PubMed ID: 7655391 [TBL] [Abstract][Full Text] [Related]
26. Cyclosporin A-induced autologous graft-versus-host disease: a prototypical model of autoimmunity and active (dominant) tolerance coordinately induced by recent thymic emigrants. Wu DY; Goldschneider I J Immunol; 1999 Jun; 162(11):6926-33. PubMed ID: 10352315 [TBL] [Abstract][Full Text] [Related]
27. Relationship of cyclosporine A-mediated inhibition of clonal deletion and development of syngeneic graft-versus-host disease. Bryson JS; Caywood BE; Kaplan AM J Immunol; 1991 Jul; 147(2):391-7. PubMed ID: 2071889 [TBL] [Abstract][Full Text] [Related]
28. T-helper lymphocytes and syngeneic graft-versus-host disease. Bos GM; Majoor GD; van de Gaar MJ; van Breda Vriesman PJ Transplant Proc; 1989 Feb; 21(1 Pt 3):3016-7. PubMed ID: 2523170 [No Abstract] [Full Text] [Related]
29. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2. Weiss L; Lubin I; Factorowich I; Lapidot Z; Reich S; Reisner Y; Slavin S J Immunol; 1994 Sep; 153(6):2562-7. PubMed ID: 8077666 [TBL] [Abstract][Full Text] [Related]
30. Use of lymphokine-activated killer cells to prevent bone marrow graft rejection and lethal graft-vs-host disease. Azuma E; Yamamoto H; Kaplan J J Immunol; 1989 Sep; 143(5):1524-9. PubMed ID: 2668409 [TBL] [Abstract][Full Text] [Related]
31. Regulation of syngeneic graft-versus-host disease by autosuppressor mechanisms. Hess AD; Fischer AC; Beschorner WE Transplant Proc; 1989 Feb; 21(1 Pt 3):3013-5. PubMed ID: 2523169 [No Abstract] [Full Text] [Related]
32. Requirements for the induction and adoptive transfer of cyclosporine-induced syngeneic graft-versus-host disease. Fischer AC; Beschorner WE; Hess AD J Exp Med; 1989 Mar; 169(3):1031-41. PubMed ID: 2647891 [TBL] [Abstract][Full Text] [Related]
33. Intermediate TCR cells with self-reactive clones are effector cells which induce syngeneic graft-versus-host disease in mice. Osman Y; Watanabe T; Kawachi Y; Sato K; Ohtsuka K; Watanabe H; Hashimoto S; Moriyama Y; Shibata A; Abo T Cell Immunol; 1995 Dec; 166(2):172-86. PubMed ID: 7497519 [TBL] [Abstract][Full Text] [Related]
34. Defective thymic education of L3T4+ T helper cell function in graft-vs-host mice. Fukuzawa M; Via CS; Shearer GM J Immunol; 1988 Jul; 141(2):430-9. PubMed ID: 2968400 [TBL] [Abstract][Full Text] [Related]
36. The role of cyclosporine-induced autoreactive T lymphocytes in solid organ allograft survival and chronic rejection. Zhang H; Horwitz L; Ruvolo P; Colombani P; Hess AD Transplantation; 1995 Jul; 60(2):115-22. PubMed ID: 7624952 [TBL] [Abstract][Full Text] [Related]
37. Modulation of graft-versus-host disease: role of regulatory T lymphocytes. Hess AD Biol Blood Marrow Transplant; 2006 Jan; 12(1 Suppl 2):13-21. PubMed ID: 16399597 [TBL] [Abstract][Full Text] [Related]
38. Two phenotypically distinct populations of T cells have suppressor capabilities simultaneously in the maintenance phase of immunologic enhancement. Padberg WM; Lord RH; Kupiec-Weglinski JW; Williams JM; Di Stefano R; Thornburg LE; Araneda D; Strom TB; Tilney NL J Immunol; 1987 Sep; 139(6):1751-7. PubMed ID: 2957435 [TBL] [Abstract][Full Text] [Related]
39. T cell synergy in the primary MLR: proliferative kinetics, effector cell generation, and IL 2 production. Salomon DR; Cohen DJ; Williams JM; Carpenter CB J Immunol; 1984 Dec; 133(6):3075-83. PubMed ID: 6238093 [TBL] [Abstract][Full Text] [Related]
40. Cyclosporine and the immune response: basic aspects. Hess AD; Colombani PM; Esa AH Crit Rev Immunol; 1986; 6(2):123-49. PubMed ID: 2942335 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]